annb0t
Top 20
Recce Pharmaceuticals
Highlights:
First cohort in Phase I/II urinary tract infection (UTI) rapid infusion intravenous (IV) study successfully dosed 2,500mg of RECCE® 327 (R327), resulting in high peak urine concentrations, as previously demonstrated in a completed Phase I clinical trial High concentrations of R327 in urine are expected to demonstrate a rapid kill rate of bacteria in line with pre-clinical UTI study results First female safely dosed with R327 IV 2,500mg at 30-minute infusion...
>>> Read more: Recce Pharmaceuticals Announces First Cohort Dosed in RECCE® 327 Rapid Infusion Phase I/II Urinary Tract Infection (UTI) Clinical Trial
Highlights:
First cohort in Phase I/II urinary tract infection (UTI) rapid infusion intravenous (IV) study successfully dosed 2,500mg of RECCE® 327 (R327), resulting in high peak urine concentrations, as previously demonstrated in a completed Phase I clinical trial High concentrations of R327 in urine are expected to demonstrate a rapid kill rate of bacteria in line with pre-clinical UTI study results First female safely dosed with R327 IV 2,500mg at 30-minute infusion...
>>> Read more: Recce Pharmaceuticals Announces First Cohort Dosed in RECCE® 327 Rapid Infusion Phase I/II Urinary Tract Infection (UTI) Clinical Trial
